Keyphrases
Myelofibrosis
100%
Myeloproliferative Neoplasms
61%
Ruxolitinib
47%
Polycythemia Vera
44%
Acute Myeloid Leukemia
25%
Essential Thrombocythemia
22%
Pacritinib
16%
Primary Myelofibrosis
14%
JAK Inhibitors
13%
JAK2V617F
13%
Splenomegaly
12%
Thrombocytopenia
10%
Janus Kinase 1 (JAK1)
10%
Phase II Study
10%
High Risk
10%
JAK2 Inhibitor
10%
Janus Kinase Inhibitors
9%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
9%
Hematopoietic Stem Cells
9%
Symptom Burden
9%
Anemia
8%
Cytopenia
8%
Myeloid Malignancies
8%
Spleen Volume
8%
Overall Survival
8%
Janus Kinase 2 (JAK2)
8%
Hematological Malignancies
7%
Hydroxyurea
7%
Disease Progression
7%
Portal Vein Thrombosis
7%
Blast Phase
7%
Bone Marrow Fibrosis
6%
Chronic Myeloid Leukemia
6%
Interferon-α (IFN-α)
6%
Leukemia Patients
6%
Therapeutic Potential
6%
Volume Reduction
6%
Pelabresib
5%
Novel Therapeutics
5%
Anticoagulation
5%
Monotherapy
5%
Patient Characteristics
5%
Combination Therapy
5%
Pegylated Interferon
5%
Fedratinib
5%
Philadelphia-negative Myeloproliferative Neoplasms
5%
Murine Double Minute 2 (MDM2)
5%
Medicine and Dentistry
Myelofibrosis
77%
Myeloproliferative Neoplasm
38%
Ruxolitinib
31%
Polycythemia vera
31%
Acute Myeloid Leukemia
22%
Essential Thrombocythaemia
16%
Disease
14%
Janus Kinase Inhibitor
13%
Overall Survival
11%
Pacritinib
10%
Splenomegaly
10%
Myeloid metaplasia
9%
Hematopoietic Cell
9%
Myeloid Malignancy
8%
Thrombocytopenia
8%
Janus Kinase
7%
Arm
7%
Clinical Trial
7%
Anemia
6%
Portal Vein Thrombosis
6%
Neoplasm
6%
Cytopenia
5%
Diseases
5%
Platelet
5%
Anticoagulation
5%
Myelodysplastic Syndrome
5%
Allogeneic Hematopoietic Stem Cell Transplantation
5%
Pharmacology, Toxicology and Pharmaceutical Science
Myelofibrosis
78%
Ruxolitinib
44%
Polycythemia vera
31%
Myeloproliferative Neoplasm
25%
Janus Kinase Inhibitor
18%
Pacritinib
15%
Thrombocythemia
14%
Acute Myeloid Leukemia
14%
Disease
12%
Thrombocytopenia
10%
Splenomegaly
9%
Overall Survival
9%
Janus Kinase
8%
Clinical Trial
7%
Myeloid metaplasia
7%
Janus Kinase 2 Inhibitor
7%
Adverse Event
7%
Hydroxycarbamide
7%
Cytopenia
6%
Combination Therapy
6%
Interferon
6%
Anemia
6%
Diseases
5%